Skip To Main Content
Andre Baruchel on Muck Rack

Andre Baruchel

As seen in: Nature, Wiley Online Library, ScienceDirect, The Lancet, European Journal of Cancer
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Andre

Contact Andre, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Tisagenlecleucel for post-transplant relapse in young acute lymphoblastic leukemia patients: European real-world determinants of outcome

|
By Laura Moser, Martin Hutter, Anna Alonso-Saladrigues, Andishe Attarbaschi, Francis Ayuk, Claudia D. Baldus, Adriana Balduzzi, Halvard Bönig, Jean-Pierre Bourquin, Jochen Buechner, Veit L. Buecklein, Saskia Burridge, Friso G. Calkoen, Gunnar Cario, Barbara De Moerloose, Marie-Emilie Dourthe, Tobias Feuchtinger, Anna Füreder, Julia Hauer, Marianne Ifversen, Andrea Jarisch, Krzysztof Kalwak, Jan-Henning Klusmann, Guido Kobbe, Christian Koenecke, Annette Künkele, Roland Meisel, Pietro Merli, Monika Mielcarek-Siedziuk, Fabian Muller, Ingo Müller, Sara Napolitano, Macarena Oporto Espuelas, Olaf Penack, Florence Rabian, Claudia Rössig, Martin G. Sauer, Arend von Stackelberg, Brigitte Strahm, Semjon Willier, Peter Bader, Susana Rives, Nicolas Boissel, Franco Locatelli, Sara Ghorashian, Andre Baruchel, Martina Ahlmann, Gustavo de Oliveira Canedo, Paul G. Schlegel
| Nature Verified
Abstract This multicenter real-world study identifies critical determinants of outcome for tisagenlecleucel (tisa-cel) in treating post-HSCT relapse in 220 children/young adults with B-ALL from 31 European centers. Median follow-up was 30.0 months, with a 43.6% 2-year event-free survival (EFS), 67.2% overall-survival (OS), and 57.1% incidence of CAR-T failure.
Open in Who Shared Issue with article?

Long-term complications after total body irradiation in children younger than 4 years transplanted for acute lymphoblastic leukemia

|
By Julie Berbis, Gerard Michel, Carine Domenech, Cécile Pochon, Cécile Renard, Andre Baruchel, Mony Fahd, Virginie Gandemer, Charlotte Jubert, Stéphane Ducassou, Catherine Paillard, Laura Olivier-Gougenheim, Alexandre Theron, Caroline Thomas, Marie-Dominique Tabone, Guy Leverger, Pascal Auquier, Jean-Hugues Dalle, Paul Saultier, Quentin Neven, Sandrine Visentin, Marilyne Poirée, Corinne Armari-Alla, Justyna Kanold, Sandrine Thouvenin-Doulet, Mathilde Veneziano Broccia
| Nature Verified
Abstract Total body irradiation (TBI)-based conditioning is the standard regimen for allogeneic hematopoietic stem cell transplantation (HSCT) in high-risk or relapsed pediatric acute lymphoblastic leukemia (ALL), but is variably used before age 4 because of concerns about long-term toxicity.
Open in Who Shared Issue with article?

Genomic fusion breakpoints for DNA-based measurable residual disease monitoring in pediatric acute lymphoblastic leukemia

|
By Chloé Arfeuille, Marion Strullu, Andre Baruchel, Hélène Cavé, Aurélie Caye-Eude, Arno H. Houtman
| Nature Verified
Abstract Measurable residual disease (MRD) is a key prognostic factor in pediatric acute lymphoblastic leukemia (ALL), but current gold-standard methods based on immunoglobulin/T-cell receptor (IG/TCR) rearrangements are complex and not informative in a subset of patients. Genomic breakpoints of oncogenic fusions (GFBs) are stable, biologically grounded markers that may overcome these limitations and improve MRD assessment.
Open in Who Shared Issue with article?
See all 15 articles